JAK Inhibitor denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for jak inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies JAK Inhibitors for Medical Necessity — and Why You Can Appeal

Cigna's medical-necessity denials for JAK inhibitors (a class of oral targeted therapies used in conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and related inflammatory diseases) typically reflect a disagreement between the plan's internal clinical criteria and the clinical picture documented in your chart. These denials are among the most successfully appealed, because the documentation to support medical necessity is almost always present — it simply needs to be assembled and presented in the right structure.

## Why This Denial Happens

Cigna applies a proprietary medical-necessity definition that requires evidence of inadequate response, intolerance, or contraindication to earlier lines of therapy, as well as a confirmed diagnosis and documented clinical severity. When the submitted prior-authorization request omits key documentation — prior therapy history, objective disease-activity measures, or an explicit statement of why the prescribed JAK inhibitor is appropriate — Cigna deniers frequently cite insufficient evidence of medical necessity.

## Your Appeal Rights

You have layered federal protections:

• ERISA §503 (employer-sponsored plans): requires a full-and-fair review with access to the clinical criteria used in the denial.
• ACA §2719 External Review: after exhausting internal appeals, most plans must offer an independent external review. The standard window to request external review is approximately four months from the final internal denial; verify the exact deadline on your denial letter. An expedited track (typically 72-hour turnaround) is available when your health could be seriously harmed by delay.
• State Insurance Regulation: if your plan is a fully-insured commercial plan (not self-funded ERISA), additional state-level protections may apply.

## Concrete Appeal Process

1. Request the full clinical-criteria document Cigna used to deny your claim — you are entitled to it under ERISA. 2. Submit a written internal appeal within the timeframe stated on the denial letter (commonly 180 days). 3. If the internal appeal is denied, request external review immediately — do not wait. 4. Consider requesting an expedited review if the condition is serious and delay causes harm.

## Documentation to Gather

• Diagnosis confirmation: specialist notes, relevant lab or imaging results confirming the diagnosis and its severity.
• Prior-treatment history: a dated, outcome-annotated list of every prior therapy tried, showing which agents were used, for how long, and why each was inadequate (lack of efficacy, intolerance, or contraindication).
• Clinical severity: current objective disease-activity scores and functional-impairment documentation from your chart.
• Prescriber medical-necessity letter: a detailed letter from your treating physician explaining why this specific JAK inhibitor is the appropriate next step, citing the FDA-approved prescribing label and the relevant specialist-society guideline (for example, the applicable ACR or AAD guideline for your condition).

## Criteria-Mapping Structure

Obtain the exact eligibility requirements from two sources: (1) the FDA-approved prescribing information for the specific JAK inhibitor prescribed, and (2) Cigna's published medical-coverage policy for this drug class. Then build a two-column table: in the left column, quote each requirement verbatim; in the right column, cite the specific chart note, date, lab result, or letter that satisfies it. This structure directly addresses each denial ground and makes the reviewer's job straightforward.